Life Extension Up To 37% For Rapamycin & Acarbose In Latest ITP Results

TL;DR

The NIA's study on mice shows that a combination of rapamycin and anacarbose extends lifespan by 37% in male mice, with potential benefits for females as well.

Transcript

foreign this is Richard from Modern Health span the interventions testing program or ITP of the Nia has released a paper with their results from the 2017 cohort of mice as it says in the title they saw a lifespan benefit from a combination of rapamycin and their Cabos and captopril with the best result showing a 37 extension of medium lifespan in t... Read More

Key Insights

• 🕵️‍♂️ The combination of rapamycin and anacarbose showed the most significant increase in lifespan, with a 37% extension in male mice.
• 🕵️‍♀️ Captopril extended female lifespan, while other interventions did not have a significant impact.
• 🐭 Genetically heterogeneous mice were used to provide more applicable results.
• 🛀 Using two out of three sites' data instead of including the University of Texas results still showed significant lifespan extensions for rapamycin and anacarbose combinations.
• ❓ The study also explored possible mechanisms for the synergistic effects of rapamycin and anacarbose.
• 🛟 Ketone precursor butanadiol tended towards life extension, and the branched-chain amino acid leucine did not have a significant negative impact.

Questions & Answers

Q: What were the most effective interventions in extending lifespan in the NIA's study?

The combination of rapamycin and anacarbose showed the most significant increase in lifespan, with a 37% extension in male mice. Captopril also extended female lifespan, although to a lesser extent.

Q: What previous interventions have been shown to extend lifespan in mice?

The NIA previously found that glycine, an NSAID-like substance, and rapamycin alone can increase lifespan in mice. However, in the 2017 study, the combination of rapamycin and anacarbose showed superior results.

Q: What is the significance of using genetically heterogeneous mice in the NIA's study?

Genetically heterogeneous mice provide more applicable results compared to inbred mice, as they represent a more diverse population. This increases the likelihood of finding interventions that can extend lifespan in a broader range of individuals.

Q: How did the lifespan of the control group at the University of Texas affect the study's results?

The control group at the University of Texas had unexpectedly short lifespan, which made the lifespan extension of the interventions group appear more significant. The data was analyzed both with and without the University of Texas group to present both sets of results.

Key Insights:

• The combination of rapamycin and anacarbose showed the most significant increase in lifespan, with a 37% extension in male mice.
• Captopril extended female lifespan, while other interventions did not have a significant impact.
• Genetically heterogeneous mice were used to provide more applicable results.
• Using two out of three sites' data instead of including the University of Texas results still showed significant lifespan extensions for rapamycin and anacarbose combinations.
• The study also explored possible mechanisms for the synergistic effects of rapamycin and anacarbose.
• Ketone precursor butanadiol tended towards life extension, and the branched-chain amino acid leucine did not have a significant negative impact.
• The results suggest that further investigation of captopril and other interventions may be valuable.

Summary & Key Takeaways

• The NIA's intervention testing program (ITP) tested various interventions on mice and found that the combination of rapamycin and anacarbose showed the most significant increase in lifespan.

• The study also showed that captopril extended lifespan in female mice, but not in males. Other interventions did not result in significant improvements.

• The ITP focuses on genetically heterogeneous mice to provide more applicable results and tests interventions at three different sites simultaneously.